BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
- Posted on August 19, 2026
- By CNBC
- 1 Views
- 1 min read
In brief
BioMarin Pharmaceutical strengthens its rare disease portfolio through a strategic $275 million acquisition of Alesta Therapeutics. This deal marks a significant investment in advancing innovative treatments for skeletal disorders, expanding BioMarin's capabilities in the specialized segment of bone disease therapeutics. The acquisition demonstrates the company's commitment to developing breakthrough solutions for patients with rare genetic and metabolic bone conditions.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions.
